Evidence map›Paper›PMID 25908486›Full record

Trial reportAmerican journal of ophthalmology2015

Pro-Permeability Factors After Dexamethasone Implant in Retinal Vein Occlusion; the Ozurdex for Retinal Vein Occlusion (ORVO) Study.

Peter A Campochiaro, Gulnar Hafiz, Tahreem A Mir, Adrienne W Scott, Raafay Sophie, Syed M Shah, Howard S Ying, Lili Lu, Connie Chen, J Peter Campbell and 8 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of ophthalmology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Intravitreal Dexamethasone Implant in Vitreoretinal Surgery: An Overview of the Literature.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Retinal vascular occlusions.Lancet (London, England) · 2020
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Peter A CampochiaroThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: pcampo@jhmi.edu.
Gulnar HafizThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Tahreem A MirThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Adrienne W ScottThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Raafay SophieThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Syed M ShahThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Howard S YingThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Lili LuThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Connie ChenThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
J Peter CampbellThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Saleema KheraniThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Ingrid Zimmer-GallerThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Adam WenickThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Ian HanThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Yannis PaulusThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Akrit SodhiThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Guohua WangThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Jiang QianThe Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Johns Hopkins University · US

Funding

Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI Ji Yi · 1985 to 2026
$22.1M
HIF dysregulation as a novel genetic model to study retinal neovascular disease.K08EY021189 · NEI · JOHNS HOPKINS UNIVERSITY · PI SODHI, AKRIT SINGH · 2011 to 2015
$898k
NEI NIH HHS EY01765NEI NIH HHS K08 EY021189NEI NIH HHS P30 EY001765
6 · The paper itself

Abstract

purposeTo correlate aqueous vasoactive protein changes with macular edema after dexamethasone implant in retinal vein occlusion (RVO).

designProspective, interventional case series.

methodsTwenty-three central RVO (CRVO) and 17 branch RVO (BRVO) subjects with edema despite prior anti-vascular endothelial growth factor (VEGF) treatment had aqueous taps at baseline and 4 and 16 weeks after dexamethasone implant. Best-corrected visual acuity (BCVA) and center subfield thickness were measured every 4 weeks. Aqueous vasoactive protein levels were measured by protein array or enzyme-linked immunosorbent assay.

resultsThirty-two vasoactive proteins were detected in aqueous in untreated eyes with macular edema due to RVO. Reduction in excess foveal thickness after dexamethasone implant correlated with reduction in persephin and pentraxin 3 (Pearson correlation coefficients = 0.682 and 0.638, P = .014 and P = .003). Other protein changes differed among RVO patients as edema decreased, but ≥50% of patients showed reductions in hepatocyte growth factor, endocrine gland VEGF, insulin-like growth factor binding proteins, or endostatin by ≥30%. Enzyme-linked immunosorbent assay in 18 eyes (12 CRVO, 6 BRVO) showed baseline levels of hepatocyte growth factor and VEGF of 168.2 ± 20.1 pg/mL and 78.7 ± 10.0 pg/mL, and each was reduced in 12 eyes after dexamethasone implant.

conclusionsDexamethasone implants reduce several pro-permeability proteins providing a multitargeted approach in RVO. No single protein in addition to VEGF can be implicated as a contributor in all patients. Candidates for contribution to chronic edema in subgroups of patients that deserve further study include persephin, hepatocyte growth factor, and endocrine gland VEGF.

Indexed as

AgedAged, 80 and overDexamethasoneDrug ImplantsEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesGlucocorticoidsHumansIntravitreal InjectionsMaleMiddle AgedPermeabilityProspective StudiesRetinal Vein OcclusionTomography, Optical CoherenceDexamethasoneDrug ImplantsGlucocorticoids

Identifiers

PMID25908486
PMCPMC6600806
OpenAlexW2149400551

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.